Peptides for Weight Management

Peptide-based weight management is the fastest-moving area in the entire compound landscape. PeptideTrace tracks 24 compounds in this space — but what makes it unusual is the pipeline. Only 4 are currently approved (semaglutide, tirzepatide, liraglutide, and setmelanotide), yet 15 more are in active clinical trials, making this the most heavily invested pipeline of any peptide research area.

The approved compounds alone have reshaped metabolic medicine. Semaglutide and tirzepatide between them account for the most commercially significant peptide launches in history, with clinical trial programmes enrolling tens of thousands of participants across multiple indications. But the next wave may be more significant still — retatrutide, CagriSema, survodutide, and orforglipron are all in late-stage trials targeting greater efficacy, oral delivery, or combination mechanisms that go beyond what current treatments offer.

The research compound tier includes older molecules like AOD-9604 and HGH Fragment 176-191, which circulate widely in grey-market channels despite limited clinical evidence. PeptideTrace tracks these alongside the clinical pipeline to give a complete picture — what’s proven, what’s promising, and what’s speculative.